News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Subscribe To Our Newsletter & Stay Updated
